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Abstract
Background Hepatitis C (HCV) is a common cause of morbidity among patients who attend general practitioners
(GPs) in Ireland for methadone maintenance treatment.
Aims To describe the development and content of guidelines for the management of HCV among current or former
opiate users in the Eastern Regional Health Authority area attending GPs for methadone treatment.
Methods The guidelines were produced in five stages: identification of key stakeholders; development of evidence-
based draft guidelines; discussion of content; determination of 'Delphi'-facilitated consensus and review by a sample
of GPs for whom the guidelines would be intended.
Results The guidelines contain advice for GPs on all aspects of care of patients at risk of HCV, including general and
preventative care, care of other bloodborne and hepatotoxic viruses, and the factors to be considered and
appropriate evaluation prior to referring a patient for assessment at a hepatology unit.
Conclusions GPs have an important role to play in the care of patients at risk of, or infected with, HCV.
Introduction
An estimated 62-81% of injecting drug users in the Dublin
area have been infected with hepatitis C (HCV)1' which will
be responsible for significant morbidity and mortality.
According to a computer cohort simulation of the natural
history of HCV carried out in a US population, Wong et al
showed that between the years 2010 and 2019 the virus will
be responsible for the loss of 1.83 million years of life in
patients under 65 years at a cost of $10.7 billion in direct
medical expenditure.4
GPs are increasingly involved in the care of drug users, with
methadone maintenance treatment being provided in general
practice.5 GPs have a key role to play in the detection and
management of HCV. Screening, counselling and identifying
patients who will benefit from referral for antiviral treatment
are strategies by which general practice might play an
active role in minimising the harm resulting from HCV in
coming years.
The management of HCV is unclear and clinical guidelines
are a useful tool in improving the quality of care.6 Guidelines
should be evidence-based, feasible for primary care, relevant
and acceptable to doctors, practice staff and patients.7 Also
they should be valid, reliable, reproducible, applicable to
common clinical situations, flexible and clear; their
development should be the product of a multidisciplinary
team subject to clinical review.11 The active participation of the
intended recipients in the process is essential and leads to a
greater sense of ownership among those expected to
implement them.910
This study describes the development and content
of guidelines for the management of HCV among current
or former drug users attending general practice in the
Eastern Regional Health Authority (ERHA) during 2001
and 2002.
Rigid adherence to guidelines such as these is often not
possible in clinical practice, and may not be in the best interest
of the patient or may not be in accordance with the patient's
individual preferences.
Methods
Identification of key stakeholders
A multidisciplinary group was formed with representatives
reflecting the range of medical and paramedical professionals
involved in the care both of those who are at risk of becoming
and those who have become infected with the HCV virus.
Physicians working in each of the areas in which HCV impacts
were invited to participate and to nominate other professionals
who might have special insights.
Draft guideline development
A Medlinc literature search was performed using the search
terms 'hepatitis C, 'HCV and 'non-A, non-B hepatitis1 with the
following terms: 'general practice'; 'family practice'; 'primary
care'; 'guidelines'; 'protocols'; 'care'; and 'management'. The
relevant articles were retrieved. Several professional
organisations' publications were reviewed and protocols for the
management of HCV reviewed.
The identified information was summarised under five
categories: general aspects of care; care of other bloodborne
viruses; screening for HCV; initial management of patients
infected with HCV; and subsequent management of patients
infected with HCV. This document was circulated to all group
members and used as the basis of discussion and debate for
subsequent meetings.
The group met on six occasions and the minutes of the meeting
and proposed topics for discussion at subsequent meetings sent to
each. Where consensus proved elusive, a modified 'Delphi'
technique was used to help determine die beliefs of the majority of
the group. This is a survey method designed to obtain the opinions
of a group of experts. It utilises anonymity, iteration and controlled
feedback, statistical group response and expert input," and has
been used extensively by professional groups within medicine.12
Draft guidelines were sent to each member of the group, with
an accompanying questionnaire inviting comments. Returned
questionnaires were studied for common themes and suggested
changes were incorporated into the subsequent draft of the
guidelines. This process was repeated twice.
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Figure 1. Diagnostic algorithm for Hepatitis B.
Guideline review
Prior to dissemination of the guidelines, a purposive sample of
GPs was given the guidelines and interviewed regarding their
content and implementation. This process resulted in minor
additions and alterations to the guidelines as described."
Guidelines on management of hepatitis C among
drug users in general practice
General aspects of care
Advice on safe drug use
Injecting drug use is the main risk factor for HCV infection.1-2
GPs have an important role in encouraging patients to refrain
from any drug use and promoting safe drug using practices.
Patients should be advised not to share syringes, needles or other
drug-related paraphernalia.14'11
Transmission through sexual contact
The risk of sexual transmission from having intercourse with
somebody with chronic hepatitis C is low."'" There are no
recommendations for change in sexual practices for those in
monogamous relationships14 but condom use is strongly
encouraged for those with multiple partners.1518IV
Vertical transmission
The prevalence of mother to child transmission is 0-6%.I1UO23
Transmission is associated with high levels of maternal HCV-
RNA24 and co-infection with HIV." Data on transmission are
limited, but indicate no difference between vaginal deliver}' and
delivery by Caesarean section.-4-1" HCV infection should not be
a factor in determining mode of delivery, except where the
patient is also HIV positive.14 The risk of transmission during
breastfeeding is low."1
Care of other bloodborne and hepatotoxic viruses
Hepatitis B infection
The course of liver disease in patients infected with HCV and
either hepatitis B (HBV) or hepatitis A (HAV) is more
aggressive.'029 All patients at risk of HCV should be tested for the
presence of, or immunity to, HBV infection (see Figure 1)'° and
HAV infection.
The presence of Hep B surface antigen (HBsAg) in the serum
indicates acute infection or chronic carrier status. The person may
or may not be infectious. The presence of anti-hepatitis B core
antibody (Anti-HBc) indicates previous exposure to the hepatitis
B virus and may or may not have active infection. Acute infection
is indicated by the presence of high levels of IgM antibody.
Chronic infection is usually indicated by the presence of IgG
antibody. Occasionally, IgM antibody can be found in patients
with chronic infection.
In people with chronic infection (HBsAg positive and Anti-
HBc IgG positive), the presence of HBeAg indicates an actively
replicating (infective) virus, and therefore that the patient is
unlikely to clear the virus from his or her system. This is probably
the best marker for ongoing viral activity.
Immunisation guidelines for Ireland recommend that HBV
vaccine be given as three doses at 0, 1 and 6 months (see Figure
2)." In high risk cases, the vaccine should be given at 0, 1 and
2 months.
It
1st HBV vaccine
1T
2nd HBV vaccine
1T
3rd HBV vaccine
±
Check anti-HBs titre
f
Repeat full HBV
vaccine course and
recheck at 2 months
10-99
HBV booster and
recheck anti-HBs at 2
months
\
4
>99
1
HBV booster at 5
years
Figure 2. Hepatitis B vaccination schedule.
The hepatitis B vaccine contains the surface antigen, which
induces the production of anti-HBs antibody so that if the host
is subsequently exposed to the virus, the immune system
recognises this event and already has formed antibodies. The
presence of anti-HBs antibody docs not differentiate between
previous vaccination or previous infection with the virus. A
positive anti-HBc antibody indicates that the patient has
previously been exposed to the virus.
It should not be offered if the patient is suffering from an acute
febrile illness, is hypersensitive to the vaccine or is allergic to
aluminium. It should be used with caution in cases of cardiac or
pulmonary insufficiency, thrombocytopenia, bleeding disorder or
where the patient is on warfarin or heparin. Facilities for the
management of anaphylaxis should be in place in the event of a
serious hypersensitivity reaction. The vaccine should only be
administered if there is a doctor on site.
Hepatitis A infection'0
This is the most common cause of viral hepatitis worldwide. It is
transmitted by the faeco-oral route. It usually causes a mild self-
limiting illness, manifesting as jaundice, diarrhoea, vomiting and
flu-type symptoms but in HCV positive patients it can cause
fulminant hepatitis.
Anti-HAV IgM indicates acute infection. The presence of
anti-HAV IgG indicates viral clearance. Chronic HAV
infection rarely occurs. Patients with HCV whose hepatic
status suddenly becomes compromised should be tested for
HAV infection.
Vaccination against HAV improves prognosis in patients with
HCV. A negative anti-HAV IgG indicates that the patient has
never been exposed to the virus and needs vaccination.
Vaccination is recommended for intravenous drug users with
chronic liver disease, persistent HBV or HCV infections.
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HIV infection
Recently, the importance of HCV-HIV co-infection in predicting a
poorer prognosis has been highlighted.32 M It is recommended that
HIV screening should be offered at the same time as screening for
HCV and, where appropriate, referral for specialist care offered.
Screening for HCV
Testing for HCV (see Figure 3)
All those at risk of hepatitis C (including injecting drug users)
should be offered testing.24-5 Furthermore, any patient with signs or
symptoms suggestive of hepatitis or requesting testing should be
tested for die virus. Where a recent test has been performed by
another agency, or where it is not possible to obtain a blood sample,
it may be appropriate to request the result of previous tests from the
National Virus Reference Laboratory which will release this
information to doctors upon receipt of a consent form signed by the
patient.
Recent generations of EIAs used to detect anti-HCV
antibodies have good sensitivity and specificity. If positive, the
laboratory will use RIBA assay or another EIA to confirm the
presence of anti-HCV.
Pre-test discussion
Having identified risk behaviours, clinical features of hepatitis or
where a patient requests HCV testing, it is important to counsel
the patient using an approach used in testing for HIV
infection.'5*6 This includes explaining the benefits and risks of
HCV testing, reassurance about confidentiality, education on
reduction of risk of transmission, discussing the risk for co-
infection with HIV or HBV and, if appropriate, offering testing
and ensuring the appropriate support is available, especially in the
event of a positive result.
Information should be given on hepatitis C, with emphasis on
the indolent nature of the illness. Patients should be told that not
everyone with HCV antibodies will have continuing infection or
will develop liver disease.:4-'7
Post-test discussion
The need to give the results personally should be emphasised during
the pretest discussion.18 Where possible, results should be given by
the person who initially discussed the test widi the patient.
Positive result
Delivery of a positive result can be a serious emotional shock to die
patient. Support should be pro\ided and the patient allowed time
to recover. It may be possible to give important information, such
as the need for further assessment and monitoring, but this should
be reinforced at subsequent consultations.
Although prognostic information cannot be exact at this early
stage, it is useful to point out the often indolent course of HCV
and that monitoring may be the only management required.
Patients with concerns about transmission should be advised that
the risks of vertical24-5 and sexual141617 transmission are low. It is
recommended that the sharing of razor blades and toothbrushes
be avoided. The presence of HCV antibody does not protect
against re-infection and therefore patients should be advised
against continued risk activity.
It is important to emphasise that the presence of antibody to
HCV alone is evidence of previous exposure to the virus, not
evidence of chronic infection and that an HCV-PCR test is
required to determine the presence of active viraemia.
Negative result
If potential exposure to the virus has occurred within the
previous six months, repeat testing should be offered. If
continued potential exposure to the virus is an issue, then repeat
testing should be offered at intervals of 12 months.
Initial management of patients infected with HCV(see Figure 4)
General advice
After diagnosis, initial advice should include how patients can
reduce the risk of developing further liver injury.24 This includes
reducing alcohol consumption, IS.19J5.39.40 abstaining from further
injecting drug use (or engaging in safe drug-using practices)/7
adopting a healthy diet,41 vaccination against HAV and HBV30
and avoiding hepatotoxic medication. Where an analgesic or an
antipyretic is required, paracetamol should be the drug of first
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Figure 3. Screening for hepatitis C — diagnostic algorithm. (Based on Royal Australian College of General
Practitioners/Australian National Council on AIDS and related diseases algorithms.)46
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choice. Patients should be encouraged to consult with their GP
early in such situations.24
Weight reduction should be recommended in obese patients as
obesity is associated with faster disease progression4" and a poorer
response to treatment.4'
Patients should be counselled on how to avoid transmitting the
virus to others.-4 People infected with HCV should not donate
organs, tissues, blood or semen.IS They should not share
toothbrushes, razor blades or other domestic items that may have
blood on them. Cuts or abrasions on the skin should be covered.24
People with one long-term sexual partner do not need to
change their sexual practices,17 IM but should be encouraged to
discuss the issue with their partner.24
In women, the risk of mother to infant transmission is 0-6%.20'~*
HCV infection is not a factor in determining the mode of
delivery, except where the patient is also HIV positive.14 There is
no risk of transmission during breastfeeding."1
HCV is not spread by contact such as coughing, sneezing,
hugging, food or water, shared eating utensils or drinking glasses.
Patients should not be excluded from work, school, play,
childcare or other settings on the basis of HCV status.24
Support and follow up
GPs should identify the psychosocial supports available to
patients and their families at the time of diagnosis.'" At the initial
consultation, a follow up appointment should be given at which
any questions or concerns the patient or the patient's family may
have can be dealt with.
Subsequent management of patients with
hepatitis C
Having determined that a patient is HCV positive by both ELISA
and RIBA testing, consideration should be given to antiviral
treatment. HCV-PCR testing should be performed, and where-
positive, liver biopsy is recommended. The decision on antiviral
therapy can only be made after a liver biopsy has confirmed
chronic active liver disease.24
The following criteria help clinicians predict which patients
benefit from therapy. However, if a clinician feels that the patient
would benefit from referral or indeed if the patient expresses a
strong preference to see a hepatologist despite not fulfilling these
criteria, then referral is appropriate.
• The individual should be HCV-PCR positive, or be strongly
RIBA positive. (To minimise false negative PCR, serum
should be separated within 2-4 hours of collection and stored
at -20°C.)w
• The individual should be free from non-prescribed opiate use
for at least six months
• The individual should be free from unstable cocaine use for at
least six months
• The individual should not be using benzodiazepines or
tricyclic antidepressants except in prescribed therapeutic doses
• Alcohol intake should be less than the recommended 21 units
per week in men and 14 units per week in women4'
• If the individual has concurrent, significant psychiatric
morbidity, evaluation by a psychiatrist may be necessary prior
to initiating antiviral therapy
• Major concurrent social problems with lack of support
structures, in some instances, may be an indication for
delaying initiation of therapy.
The decision on whether the patient would benefit from
diagnostic and therapeutic interventions at a specialist clinic
should be the product of a shared decision-making process
between doctor and patient. To facilitate a rapid assessment of
patients at the hepatology clinic, it is essential to provide the
following information (where available) upon referral:
• Results of HCV screening test and, if available, subsequent
PCR/genotype testing (and a copy of the results)
• Clinical evaluation of liver status
• Results of LFT/FBC
• Contact address or telephone number for correspondence
with patient
• Is the patient free from unstable drug use?
It is also useful to provide the following information, if available,
upon referral:
• Results of tests for other bloodborne viruses (including HIV
and HBV)
• Details of vaccinations against hepatitis B and A
• Duration of methadone therapy and dose
• Whether or not the potential risks and benefits of treatment
have been discussed with the patient.
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Figure 4. Management of patients who are HCV antibody
positive.
Conclusions
HCV is a common infection among patients who attend GPs for
methadone maintenance treatment. The morbidity associated
with chronic HCV infection is significant.
This paper outlines the role GPs can play in caring for people
at risk of HCV based on our understanding of the epidemiology,
diagnosis and treatment of HCV infection at the time of
development of these guidelines, particularly with regard to:
reducing the number of incident cases; determining the
prevalence; appropriately managing other risk factors for chronic
liver disease; and facilitating assessment for antiviral therapy.
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